Oncoplasty’s Contribution in Breast Cancers: About 48 Cases

HTML  XML Download Download as PDF (Size: 841KB)  PP. 1-6  
DOI: 10.4236/oalib.1101330    454 Downloads   1,026 Views  

ABSTRACT

Introduction: Oncoplasty has developed for 20 years in order to avoid potentially major deformations of conservative treatment. We report the results of our oncoplastic breast operations. Patients and Methods: We conducted a descriptive and retrospective study of 48 patients treated by oncoplastic technique in the national center of burn and plastic surgery in the U.H. IBN-ROCHD of Casablanca between 2011 and 2014. Patient and tumor characteristics, as well as information on the procedures and complications, were collected from clinical records. Results: Forty-eight cases were reviewed. The tumors were processed for the majority of invasive ductal carcinoma pT2. Seven patients had an inadequate surgical margin. About histology, the rate of recovery for non-positive margins was significantly lower in the CCI alone than that in other types. Morbidity was 14.5% and the average delayed to adjuvant treatment of 72 days. The symmetrization rate was 24%. In terms of oncological results, during a median follow-up of 22 months, the rate of local recurrences was 13%. Conclusion: The oncoplastic operations offer tools for breast conservation in patients and otherwise is destined for mastectomy or poor esthetic outcome. This study shows that the goal of surgical therapy is to identify patients who are suitable for oncoplastic surgery. Proper pre-operative evaluation and diagnosis, surgical planning, adequacy of resection, and pathological evaluation are essential.

Share and Cite:

Rafik, A. , Douiri, M. , Bahechar, N. and Chlihi, A. (2015) Oncoplasty’s Contribution in Breast Cancers: About 48 Cases. Open Access Library Journal, 2, 1-6. doi: 10.4236/oalib.1101330.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.